"If patients have one feature, that is bad, and if they have two or more, that is really bad," he said. "Regardless of ...

Sino Biopharmaceuticals plans to pay up to nearly $951 million to acquire LaNova Medicines, which previously licensed drugs ...

GSK has been enjoying regulatory momentum in recent months as it works to bring its antibody-drug conjugate (ADC) Blenrep back to markets around the globe. | As GSK's Blenrep makes its return to ...